The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.
Satoshi Murata; Brian H Ladle; Peter S Kim; Eric R Lutz; Matthew E Wolpoe; Susan E Ivie; Holly M Smith; Todd D Armstrong; Leisha A Emens; Elizabeth M Jaffee; et al. (Profiled Authors: Leisha Emens; Elizabeth Jaffee; Todd Armstrong)
Department of Oncology, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
Journal of immunology (Baltimore, Md. : 1950) 2006;176(2):974-83.
T cell costimulation via OX40 is known to increase CD4+ T cell expansion and effector function and enhances the development of T cell memory. OX40 costimulation can also prevent, and even reverse, CD4+ T cell anergy. However, the role of OX40 in CD8+ T cell function is less well defined, particularly in the setting of immune tolerance. To determine the effects of OX40 costimulation on the induction of the host CD8+ T cell repertoire to an endogenous tumor Ag, we examined the fate of CD8+ T cells specific for the immunodominant rat HER-2/neu epitope, RNEU420-429, in FVB MMTV-neu (neu-N) mice, which express rat HER-2/neu protein in a predominantly mammary-restricted fashion. We show that the RNEU420-429-specific T cell repertoire in neu-N mice expands transiently after vaccination with a neu-targeted GM-CSF-secreting whole-cell vaccine, but quickly declines to an undetectable level. However, OX40 costimulation, when combined with GM-CSF-secreting tumor-targeted vaccination, can break established CD8+ T cell tolerance in vivo by enhancing the expansion, and prolonging the survival and effector function of CD8+ T cells specific for RNEU420-429. Moreover, we demonstrate that OX40 expression is up-regulated on both CD4+ and CD8+ T cells shortly after administration of a GM-CSF expressing vaccine. These studies highlight the increased efficacy of OX40 costimulation when combined with a GM-CSF-secreting vaccine, and define a new role for OX40 costimulation of CD8+ T cells in overcoming tolerance and boosting antitumor immunity.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Jennifer N Uram; Chelsea M Black; Emilee Flynn; Lanqing Huang; Todd D Armstrong; Elizabeth M JaffeeJournal of immunology (Baltimore, Md. : 1950) 2011;186(7):3847-57.
Matthew E Wolpoe; Eric R Lutz; Anne M Ercolini; Satoshi Murata; Susan E Ivie; Elizabeth S Garrett; Leisha A Emens; Elizabeth M Jaffee; R Todd Reilly
HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.Journal of immunology (Baltimore, Md. : 1950) 2003;171(4):2161-9.
Dung T Le; Brian H Ladle; Timothy Lee; Vivian Weiss; Xiaosai Yao; Ashley Leubner; Todd D Armstrong; Elizabeth M JaffeeInternational journal of cancer. Journal international du cancer 2011;129(3):636-47.
Appears in this Publication
Author of this Publication